Abstract
Purpose: Quantitative structure-activity studies were performed on a series of benzoquinone mustard (BM) bifunctional alkylating agents to determine whether DNA topoisomerase II (topo II) inhibition was responsible for cell growth inhibition. Methods: Topo II inhibition was evaluated by decatenation and agarose gel electrophoresis assays. Results: The BM compounds were shown to potently inhibit the decatenation activity of topo II. Though BM compounds promoted the formation of protein-DNA complexes in isolated nuclei and cells, this effect was undiminished when levels of topo II varied. The BM compounds had little activity in a topo II-mediated DNA cleavage assay, suggesting that they do not function as topo II poisons. Rather, BM-induced protein-DNA complex formation was likely due to the bifunctional alkylating reactivity of these compounds. Finally, the growth inhibitory properties of these compounds did not correlate with their ability to inhibit topo II, indicating that these compounds did not exert their cellular activity through inhibition of topo II. Some BM compounds reacted very quickly with glutathione and cysteine, likely initially through an electrophilic Michael addition. In the absence of cysteine, the growth inhibitory effects of BM were increased tenfold, indicating the modulatory effect of cysteine sulfhydryl adducts. EPR studies showed that a semiquinone-free radical was produced by some BM compounds. Conclusions: BM compounds likely exert their action through DNA cross-linking and/or by inducing oxidative stress. Although topo II is not a direct target of these agents, this enzyme may play a role in processing the consequences of direct DNA adduction and/or oxidative DNA damage.
Similar content being viewed by others
Abbreviations
- BM:
-
Benzoquinone mustard
- BSA:
-
Bovine serum albumin
- CC:
-
Closed circular DNA
- CHO:
-
Chinese hamster ovary cell line
- DMSO:
-
Dimethyl sulfoxide
- DTT:
-
Dithiothreitol
- DZR:
-
Dexrazoxane-resistant cell line derived from the parent CHO cell line
- NQO1:
-
(DT-diaphorase), NAD(P)H: quinone oxidoreductase, EC 1.6.99.2
- EDTA:
-
Ethylenediaminetetraacetic acid
- EPR:
-
Electron paramagnetic resonance
- Na2EDTA:
-
Disodium EDTA
- GSH:
-
Glutathione
- Hepes:
-
N-[2-hydroxyethyl]piperazine-N′-[2-ethanesulfonic acid]
- IC50 :
-
50% inhibitory concentration
- kDNA:
-
Kinetoplast DNA
- LIN:
-
Linear pBR322 DNA
- LUMO:
-
Energy of the lowest unoccupied molecular orbital
- MTT:
-
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
- NC:
-
Nicked circular DNA
- ROS:
-
Reactive oxygen species
- RLX:
-
Relaxed pBR322 DNA
- SC:
-
Supercoiled pBR322 DNA
- SDS:
-
Sodium dodecyl sulfate
- TAE:
-
Tris base (4 mM)/glacial acetic acid (0.11% (v/v))/Na2EDTA (2 mM) buffer Tris, tris(hydroxymethyl)aminomethane
- UV:
-
Ultraviolet
References
Alt C, Eyer P (1998) Ring addition of the α-amino group of glutathione increases the reactivity of benzoquinone thioethers. Chem Res Toxicol 11:1223–1233
Amaro AR, Oakley GG, Bauer U, Spielmann HP, Robertson LW (1996) Metabolic activation of PCBs to quinones: reactivity toward nitrogen and sulfur nucleophiles and influence of superoxide dismutase. Chem Res Toxicol 9:623–629
Bailey SM, Lewis AD, Patterson LH, Fisher GR, Knox RJ, Workman P (2001) Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species. Biochem Pharmacol 62:461–468
Baker RK, Kurz EU, Pyatt DW, Irons RD, Kroll DJ (2001) Benzene metabolites antagonize etoposide-stabilized cleavable complexes of DNA topoisomerase IIα. Blood 98:830–833
Barnabé N, Hasinoff BB (2001) High-throughput fluorescence flow injection topoisomerase II inhibition assay. J Chromatogr B Biomed Sci Appl 760:263–269
Barnabé N, Zastre J, Venkataram S, Hasinoff BB (2002) Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radic Biol Med 33:266–275
Bender RP, Lindsey RH Jr, Burden DA, Osheroff N (2004) N-acetyl-p-benzoquinone imine, the toxic metabolite of acetaminophen, is a topoisomerase II poison. Biochemistry 43:3731–3739
Bolton JL, Trush MA, Penning TM, Dryhurst G, Monks TJ (2000) Role of quinones in toxicology. Chem Res Toxicol 13:135–160
Burden DA, Froelich-Ammon SJ, Osheroff N (2001) Topisomerase II-mediated cleavage of plasmid DNA. Methods Mol Biol 95:283–289
Chen H, Eastmond DA (1995) Topoisomerase inhibition by phenolic metabolites: a potential mechanism for benzene’s clastogenic effects. Carcinogenesis 16:2301–2307
Fattman C, Allan WP, Hasinoff BB, Yalowich JC (1996) Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16) resistant human leukemia K562 cells. Biochem Pharmacol 52:635–642
Fortune JM, Osheroff N (2000) Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 64:221–253
Fourie J, Guziec F Jr, Guziec L, Monterrosa C, Fiterman DJ, Begleiter A (2004) Structure-activity study with bioreductive benzoquinone alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicity. Cancer Chemother Pharmacol 53:191–203
Fourie J, Oleschuk CJ, Guziec F Jr, Guziec L, Fiterman DJ, Monterrosa C, Begleiter A (2002) The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase. Cancer Chemother Pharmacol 49:101–110
Frantz CE, Chen H, Eastmond DA (1996) Inhibition of human topoisomerase II in vitro by bioactive benzene metabolites. Environ Health Perspect 104 Suppl 6:1319–1323
Frydman B, Marton LJ, Sun JS, Neder K, Witiak DT, Liu AA, Wang HM, Mao Y, Wu HY, Sanders MM, Liu LF (1997) Induction of DNA topoisomerase II-mediated DNA cleavage by β-lapachone and related naphthoquinones. Cancer Res 57:620–627
Gantchev TG, Hunting DJ (1997) Inhibition of the topoisomerase II-DNA cleavable complex by the ortho-quinone derivative of the antitumor drug etoposide (VP-16). Biochem Biophys Res Comm 237:24–27
Gantchev TG, Hunting DJ (1998) The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex. Mol Pharmacol 53:422–428
Hasinoff BB, Wu X, Yang Y (2004) Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl2(dexrazoxane) and cis-PtCl2(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186). J Inorg Biochem 98:616–624
Hasinoff BB, Kuschak TI, Yalowich JC, Creighton AM (1995) A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol 50:953–958
Hasinoff BB, Kozlowska H, Creighton AM, Allan WP, Thampatty P, Yalowich JC (1997) Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site. Mol Pharmacol 52:839–845
Hasinoff BB, Kuschak TI, Creighton AM, Fattman CL, Allan WP, Thampatty P, Yalowich JC (1997) Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochem Pharmacol 53:1843–1853
Hasinoff BB, Wu X, Krokhin OV, Ens W, Standing KG, Nitiss JL, Sivaram T, Giorgianni A, Yang S, Jiang Y, Yalowich JC (2005) Biochemical and proteomics approaches to characterize topoisomerase IIα cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIα. Mol Pharmacol 67:937–947
Hutt AM, Kalf GF (1996) Inhibition of human DNA topoisomerase II by hydroquinone and p-benzoquinone, reactive metabolites of benzene. Environ Health Perspect 104 (Suppl 6):1265–1269
Jensen LH, Renodon-Corniere A, Wessel I, Langer SW, Sokilde B, Carstensen EV, Sehested M, Jensen PB (2002) Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition. Mol Pharmacol 61:1235–1243
Li TK, Liu LF (2001) Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 41:53–77
Lindsey RH Jr, Bromberg KD, Felix CA, Osheroff N (2004) 1,4-Benzoquinone is a topoisomerase II poison. Biochemistry 43:7563–7574
Makarova AN, Berlin AY (1967) Bis(2-chloroethyl)amino-p-benzoquinones and their derivatives. J Gen Chem USSR 37:595–560
Mekapati SB, Hansch C (2002) On the parametrization of the toxicity of organic chemicals to tetrahymena pyriformis. The problem of establishing a uniform activity. J Chem Inf Comput Sci 42:956–961
Monks TJ, Jones DC (2002) The metabolism and toxicity of quinones, quinonimines, quinone methides, and quinone-thioethers. Curr Drug Metab 3:425–438
Neder K, Marton LJ, Liu LF, Frydman B (1998) Reaction of beta-lapachone and related naphthoquinones with 2-mercaptoethanol: a biomimetic model of topoisomerase II poisoning by quinones. Cell Mol Biol (Noisy-le-grand) 44:465–474
O’Brien PJ (1991) Molecular mechanisms of quinone cytotoxicity. Chem Biol Interact 80:1–41
Ollinger K, Brunmark A (1991) Effect of hydroxy substituent position on 1,4-naphthoquinone toxicity to rat hepatocytes. J Biol Chem 266:21496–21503
Powis G (1989) Free radical formation by antitumor quinones. Free Radic Biol Med 6:63–101
Ritke MK, Yalowich JC (1993) Altered gene expression in human leukemia K562 cells selected for resistance to etoposide. Biochem Pharmacol 46:2007–2020
Ritke MK, Allan WP, Fattman C, Gunduz NN, Yalowich JC (1994) Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells. Mol Pharmacol 46:58–66
Ritke MK, Roberts D, Allan WP, Raymond J, Bergoltz VV, Yalowich JC (1994) Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukemia K562 cells. Br J Cancer 69:687–697
Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL, Jensen PB (1998) Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: A Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Cancer Res 58:1460–1468
Siraki AG, Chan TS, O’Brien PJ (2004) Application of quantitative structure-toxicity relationships for the comparison of the cytotoxicity of 14 p-benzoquinone congeners in primary cultured rat hepatocytes versus PC12 cells. Toxicol Sci 81:148–159
Swallow AJ (1982) Physical chemistry of semiquinones. In: Trumpower BL (ed) Function of quinones in energy conserving systems. New York: Academic, pp 59–72
Wang H, Mao Y, Chen AY, Zhou N, LaVoie EJ, Liu LF (2001) Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation. Biochemistry 40:3316–3323
Wilson I, Wardman P, Lin TS, Sartorelli AC (1987) Reactivity of thiols towards derivatives of 2- and 6-methyl-1,4-naphthoquinone bioreductive alkylating agents. Chem Biol Interact 61:229–240
Workman P, Stratford IJ (1993) The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev 12:73–82
Yalowich JC, Thampatty P, Allan WP, Chee G-L, Hasinoff BB (1998) Acquired resistance to ICRF-187 (dexrazoxane) in a CHO cell line is associated with a point mutation in DNA topoisomerase IIα (topo II) and decreased drug-induced DNA-enzyme complexes. Proc Am Assoc Cancer Res 39:375
Zhu BZ, Zhao HT, Kalyanaraman B, Frei B (2002) Metal-independent production of hydroxyl radicals by halogenated quinones and hydrogen peroxide: an ESR spin trapping study. Free Radic Biol Med 32:465–473
Acknowledgments
This work was supported by the Canadian Institutes of Health Research (B.B.H. and A.B.), the Canada Research Chairs Program, and a Canada Research Chair in Drug Development (B.B.H.); the National Cancer Institute of Canada with funds from the Canadian Cancer Society (A.B.), the Dishman Endowment, Southwestern University (L.J.G. and F.G.); and by a grant from the NIH (grant CA90787) (J.C.Y.).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hasinoff, B.B., Wu, X., Begleiter, A. et al. Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II. Cancer Chemother Pharmacol 57, 221–233 (2006). https://doi.org/10.1007/s00280-005-0040-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-005-0040-5